Emyria Ltd has released a press release.
Appendix 4E Preliminary Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Emyria Launches Ketamine-Assisted Therapy Program
- Emyria advances development and commercialisation of unique drug products
- June 2023 Quarterly Activities Report and Appendix 4C
- Emyria Recruits First Patient MDMA-Assisted Therapy Trial
- Presentation - Pax Acquisition and Company Update
Later from Emyria
- Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer
- Prospectus
- Strategic Update & Entitlement Offer Presentation
- Emyria provides unique combination of drug development and therapy delivery
- Emyria Completes Acquisition of the Pax Centre
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria